# GRACE: A Phase 1/2a Study of VTRU200 in Relapsed/Refractory AML, High-risk MDS, DLBCL Post CART Failure and Advanced Solid Tumors

> **NCT07749976** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Vitruviae** · enrollment: 108 (estimated)

## Conditions studied

- Acute Myeloid Leukemia
- Diffuse Large B Cell Lymphoma (DLBCL)
- High Risk Myelodysplastic Syndrome
- Solid Tumor Malignancies
- Pediatric Acute Myeloid Leukemia

## Interventions

- **BIOLOGICAL:** VTRU200

## Key facts

- **NCT ID:** NCT07749976
- **Lead sponsor:** Vitruviae
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2027-01
- **Primary completion:** 2028-01
- **Final completion:** 2029-01
- **Target enrollment:** 108 (ESTIMATED)
- **Last updated:** 2026-08-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07749976

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07749976, "GRACE: A Phase 1/2a Study of VTRU200 in Relapsed/Refractory AML, High-risk MDS, DLBCL Post CART Failure and Advanced Solid Tumors". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07749976. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*